In a report released yesterday, Sean Lavin from BTIG maintained a Hold rating on Vital Therapies (NASDAQ: VTL). The company’s shares closed yesterday at $8.55, close to its 52-week high of $9.16.
Lavin wrote:
“Q2 earnings call revolved around the upcoming topline data from its VTL-308 trial in severe alcoholic hepatitis (sAH). The data set is expected to be locked soon and topline data will be press released in the back half of September, with a conference call to follow. We see the announcement as a binary event. Although the insights discussed during May’s R&D Day left us with a better understanding of how ELAD should work, we remain cautious. With VTL-308 targeting patients who fit specific enrollment criteria that seems more likely to show a survival benefit, we see the likelihood of positive data as better than even, but nowhere near a shoo-in (perhaps 65-35).”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 14.5% and a 62.3% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Tactile Systems Technology, and Obalon Therapeutics Inc.
Vital Therapies has an analyst consensus of Moderate Buy, with a price target consensus of $22.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.16 and a one-year low of $2.60. Currently, Vital Therapies has an average volume of 339.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vital Therapies, Inc. operates as a biotherapeutic company, which develops a human hepatic cell-based system for the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal.
